Purple Biotech Ltd (PPBT) stock forecast & analysis
1.98
NasdaqCM · USD
Up: +0.32, +19.3%
1 analysis
- Open
- 2.39
- Previous close
- 1.66
- Day range
- 1.90 – 2.59
- 52-week range
- 1.16 – 14.10
- Volume (shares)
- 76.35M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 1.63M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- -0.54
- Market cap
- 3.22M
Market Scanner’s AI analysis of Purple Biotech Ltd (PPBT), updated September 2026: Purple Biotech's recent rally driven by patent allowance and positive preclinical data, despite overbought technical indicators.
Summary
Purple Biotech's recent rally driven by patent allowance and positive preclinical data, despite overbought technical indicators.
Recent analyses for PPBT covered a significant upward price movement, with the stock trading above its 50-day and 10-day EMAs, and showing strong short-term percentage gains. This rally occurred despite longer-term downtrends and current overbought conditions indicated by the RSI and MFI. The company's financial performance showed a positive net income in the latest quarter after previous losses, alongside news of a U.S. patent allowance for its CAPTN-3 technology and positive preclinical study results for IM1240.
PPBT news & sentiment
News reports highlighted positive developments including a patent allowance and promising preclinical study results, alongside mentions in "Top Midday Gainers" lists. This news appears to have driven positive market attention and price momentum.
PPBT technical picture
The price action for PPBT showed a strong recent upward trend, trading above its 50-day and 10-day SMAs and EMAs. Momentum indicators like the MACD were positive, but the RSI and MFI suggested overbought conditions, with the price trading above the upper Bollinger Band.
Fundamentals
The company reported positive net income in its most recent quarter, a shift from prior losses. Its market capitalization was approximately $3.2 million, with a 52-week price range between $1.16 and $14.1.
Factors discussed — upside
- Positive net income reported in the latest quarter after prior losses
- U.S. patent allowance for CAPTN-3 multispecific antibody protection and platform
- Preclinical study results support advancing IM1240 to a first-in-human trial in 2027
- Strong short-term price momentum with significant 7-day and 30-day percentage gains
- Current price trading above 50-day SMA and 10-day EMA
Factors discussed — risks
- Asset in overbought territory indicated by RSI at 71.90
- Extremely strong buying pressure and potentially overbought conditions indicated by MFI at 99.87
- Current price trading above the upper Bollinger Band, suggesting potential overextension
- Longer-term downtrend indicated by a significant 91-day price decrease prior to the recent rally
- Intellectual property
- Pipeline advancement
- Technical indicators
- Financial performance
Summary updated .
PPBT technical indicators
Common technical indicators for PPBT, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 1.55 | Price above |
| 10-day exponential moving average | 1.70 | Price above |
| Relative strength index (14-day) | 71.89 | Overbought |
| MACD line (12/26/9) | 0.0546 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 1.34 – 1.84 | Price above the upper band |
Analyses
Recent PPBT.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Purple Biotech Ltd?
- The bull case for Purple Biotech centers on its recent positive net income following prior losses and the strengthening of its intellectual property through a U.S. patent allowance for its CAPTN-3 technology. Further support comes from preclinical study results indicating advancement for IM1240 and strong short-term price momentum, with the current price trading above key moving averages.
- What are the risks for Purple Biotech Ltd?
- Risks for Purple Biotech include technical indicators suggesting the asset is in overbought territory, with extremely strong buying pressure and the current price trading above the upper Bollinger Band potentially indicating overextension. Additionally, a significant 91-day price decrease prior to the recent rally suggests a longer-term downtrend.
- Is Purple Biotech Ltd bullish or bearish?
- Recent AI analyses of Purple Biotech Ltd examined factors on both sides. Discussed upside: The bull case for Purple Biotech centers on its recent positive net income following prior losses and the strengthening of its intellectual property through a U.S. patent allowance for its CAPTN-3 technology. Further support comes from preclinical study results indicating advancement for IM1240 and strong short-term price momentum, with the current price trading above key moving averages. Discussed risks: Risks for Purple Biotech include technical indicators suggesting the asset is in overbought territory, with extremely strong buying pressure and the current price trading above the upper Bollinger Band potentially indicating overextension. Additionally, a significant 91-day price decrease prior to the recent rally suggests a longer-term downtrend. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Purple Biotech Ltd?
- News reports highlighted positive developments including a patent allowance and promising preclinical study results, alongside mentions in "Top Midday Gainers" lists. This news appears to have driven positive market attention and price momentum.
- Bundles used
- gemini-low-v2
Run a fresh PPBT.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every PPBT.US report already in the library